PT  - JOURNAL ARTICLE
AU  - MORINE, YUJI
AU  - IKEMOTO, TETSUYA
AU  - IWAHASHI, SHUICHI
AU  - SAITO, YU
AU  - YAMADA, SHINICHIRO
AU  - TAKASU, CHIE
AU  - HIGASHIJIMA, JUN
AU  - IMURA, SATORU
AU  - SHIMADA, MITSUO
TI  - Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis
AID  - 10.21873/anticanres.13703
DP  - 2019 Sep 01
TA  - Anticancer Research
PG  - 5089--5096
VI  - 39
IP  - 9
4099  - http://ar.iiarjournals.org/content/39/9/5089.short
4100  - http://ar.iiarjournals.org/content/39/9/5089.full
SO  - Anticancer Res2019 Sep 01; 39
AB  - Background/Aim: We evaluated the clinical impact of FOLFOXIRI regimen aiming for conversion surgery in patients with unresectable multiple colorectal liver metastasis (CRLM). Patients and Methods: A total of 42 patients with unresectable multiple CRLM who received chemotherapy with molecular agents were included in the analysis. The clinical results of FOLFOXIRI with other regimens were compared. Results: The total conversion rate of 42 unresectable CRLM was 48.1%, and conversion cases had a better prognosis. Clinicopathological characteristics of conversion cases were more frequent in FOLFOXIRI induction, liver limited disease and maximum diameter × number (MDN) over 70. FOLFOXIRI achieved a higher conversion rate compared to other regimens (72.2% vs. 37.5%, p=0.0334), and significantly reduced the medication period until conversion surgery (median 5.8 courses) with a higher tumour necrotic rate. Consequently, the overall survival of conversion cases with FOLFOXIRI was better than that with other regimens (p=0.0055). Conclusion: FOLFOXIRI plus molecular agents might provide a higher probability of conversion surgery with a prognostic benefit.